CME Group (CME) and Nasdaq Inc (NDAQ) on Torvanta's measures: CME grades higher on 2 of the 4 factor families and NDAQ on 2.
| CME | NDAQ | |
|---|---|---|
| Value grade | D | D+ |
| Growth grade | C | B- |
| Profitability grade | B | B- |
| Momentum grade | B+ | B |
| Market value | $106.2B | $52.5B |
| P/E (trailing) | 24.9x | 27.4x |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $6.8B | $8.8B |
| Revenue growth (y/y) | +5% | +8% |
| Operating margin | 65.1% | 29.5% |
| Return on invested capital | 13.9% | 10.3% |
| Free-cash-flow yield | 4.0% | 3.7% |
| Total return, 1 year | +16.3% | +8.3% |
| Total return, 3 years | +52.7% | +94.5% |
Full CME analysis · Full NDAQ analysis
CME Group (CME) and Nasdaq Inc (NDAQ) on Torvanta's measures: CME grades higher on 2 of the 4 factor families and NDAQ on 2. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings CME trades at 24.9x and NDAQ at 27.4x; their value grades are D and D+ against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer